Drugs / IO102/IO103
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03047928 | Feb 2018 → Dec 2022 | metastatic melanoma | Inge Marie Svane | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IO102/IO103 | “We tested a first-in-class immune-modulatory vaccine (IO102/IO103) against indoleamine 2,3-dioxygenase (IDO) and PD ligand 1 (PD-L1), targeting immunosuppressive cells and...” PMID 34887574 ↗ Dec 2021 |
| Known as | IO102/IO103 peptide vaccine | “IO102/IO103 peptide vaccine” NCT03047928 ↗ |
| Modality | Vaccine | “first-in-class immune-modulatory vaccine (IO102/IO103)” PMID 34887574 ↗ Dec 2021 |